Trial Profile
Phase I tolerability study of MDT 637 in patients with respiratory syncytial virus infections.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2010
Price :
$35
*
At a glance
- Drugs MDT 637 (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions
- Sponsors MicroDose Therapeutx